Isatuximab (NCT06517017)

Name: Isatuximab trial for Multiple Myeloma (NCT06517017)
Uploaded: 2026-10-31T21:55:53.296Z
Duration: 1 min 13 s
Description: Isatuximab trial for Multiple Myeloma (NCT06517017). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06517017.

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma: a one-minute explainerNCT065170171 min

Isatuximab trial for Multiple Myeloma (NCT06517017). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed multiple myeloma or plasma-cell leukemia, a frailty score of at least three, and no more than one prior treatment cycle.

The idea: start treatment gently. Isatuximab targets CD38 on cancer cells; dexamethasone accompanies the initial treatment. Lenalidomide, which affects immune cells and cancer growth, starts in cycle three. Dexamethasone may stop after two cycles.

This phase 2 study plans 40 patients. Ghulam Rehman Mohyuddin leads at Huntsman Cancer Institute in Salt Lake City, the sole recruiting US site. Researchers measure treatment completion.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.